XtalPi enters $400m partnership for small molecule therapy for GPCR target
XtalPi stands to receive further payments based on clinical and commercial milestones, as well as future royalties.
Drug Development
EMA validates Bayer’s asundexian application for ischaemic stroke
Coya Therapeutics CEO on ALS urgency and fast-tracking COYA 302 for patient impact
Aditxt and Ignite announce merger plans with strategic partner
MHRA to roll out new AI sandbox for medicines development
J&J to acquire Firefly Bio for $1bn to enhance oncology pipeline
Pfizer’s Hympavzi secures FDA expanded indications for haemophilia
Sanofi and Owkin partner to develop next-generation biopharma AI agents
